| Authors: |
Peters S; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Piha-Paul SA; The University of Texas MD Anderson Cancer Center, Houston, TX., Sehgal K; Dana-Farber Cancer Institute, Boston, MA., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain., Bockorny B; Beth Israel Deaconess Medical Center, Boston, MA., Galvao V; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Dowlati A; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH., Fontana E; Sarah Cannon Research Institute UK, London, United Kingdom., Hernandez-Guerrero T; START Barcelona-HM Nou Delfos, Barcelona, Spain., Rivera Herrero F; Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Kingsley E; Comprehensive Cancer Centers of Nevada, Las Vegas, NV., Lopez JS; Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, United Kingdom., Patnaik A; The START Center for Cancer Research, San Antonio, TX., Perez CA; Sarah Cannon Research Institute at Florida Cancer Specialists-Lake Nona, Orlando, FL., Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR., Knowles S; Pfizer, Bothell, WA., Patilea-Vrana G; Pfizer, Bothell, WA., Li J; Pfizer, La Jolla, CA., Wang T; Pfizer, South San Francisco, CA., Wang Y; Pfizer, Bothell, WA., Hollebecque A; Institut Gustave Roussy, Villejuif, France. |
